Dilated cardiomyopathy: from genes and molecules to potential treatments

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Dilated cardiomyopathy (DCM) is characterized by ventricular enlargement and impaired systolic function, often leading to congestive heart failure.
• Familial inheritance is significant in DCM, with pathogenic gene mutations identified in approximately 50% of affected individuals.
• Key genes implicated in DCM include TTN, LMNA, and MYH7, with ongoing research exploring their roles.

Purpose of the Study:

• To highlight the genetic underpinnings of dilated cardiomyopathy.
• To emphasize the importance of genetic testing in diagnosis.
• To discuss current and emerging therapeutic strategies for DCM.

Main Methods:

• Review of existing literature on dilated cardiomyopathy genetics and pathogenesis.
• Analysis of common genetic mutations associated with DCM.
• Exploration of diagnostic approaches including genetic testing.
• Overview of current treatment modalities and novel preclinical research.

Main Results:

• Genetic mutations, particularly in TTN, LMNA, and MYH7, are major contributors to DCM.
• Myocardial inflammation, metabolic abnormalities, and cardiomyocyte apoptosis are crucial in DCM pathogenesis.
• Genetic testing is increasingly vital for precise and prompt clinical diagnosis of DCM.
• Heart transplantation remains the primary treatment, but donor scarcity necessitates alternative therapies.

Conclusions:

• Understanding the genetic basis of DCM provides critical targets for future treatments.
• Integrated diagnostic approaches combining clinical evaluation, imaging, and genetic testing are essential.
• Novel therapeutic avenues, including stem cell therapy, are under investigation to address unmet needs in DCM management.